Given that fascin is now a widely recognised prognostic marker of metastatic disease, it will be important to investigate whether strategies targeted towards dual inhibition or modulation of fascin–actin and fascin–MT binding can slow or restrict invasive disease. This evidence concerns the gene FSCN1 and metastatic neoplasm.